Tech Company Financing Transactions
Versartis Funding Round
On 6/2/2009, Versartis raised $11 million in Series A funding from Index Ventures.
Transaction Overview
Company Name
Announced On
6/2/2009
Transaction Type
Venture Equity
Amount
$11,000,000
Round
Series A
Investors
Index Ventures (Roman Fleck)
Proceeds Purpose
The funds raised will be used to progress its novel compounds into human clinical trials.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
275 Shoreline Dr. 450
Mountain View, CA 94065
USA
Mountain View, CA 94065
USA
Phone
Website
Email Address
Overview
Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Shepard
Chief Financial Officer
Joshua Brumm
Chief Medical Officer
George Bright
VP - Bus. Development
Paul Westberg
VP - Manufacturing
Patrick Murphy
VP - Operations
Eric Humphriss
VP - Product Management
Rajendra Mohabir
Browse more venture capital transactions:
Prev: 6/2/2009: Polatis venture capital transaction
Next: 6/2/2009: Catheter Connections venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs